このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Incyte マネジメント

マネジメント基準チェック /44

Incyte'sの CEO はHerve Hoppenotで、 Jan2014年に任命され、の在任期間は 10.42年です。の年間総報酬は$ 16.66Mで、 7.8%給与と92.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.15%を直接所有しており、その価値は$ 21.47M 。経営陣と取締役会の平均在任期間はそれぞれ8.4年と7.4年です。

主要情報

Herve Hoppenot

最高経営責任者

US$16.7m

報酬総額

CEO給与比率	7.8%
CEO在任期間	10.4yrs
CEOの所有権	0.2%
経営陣の平均在職期間	8.4yrs
取締役会の平均在任期間	7.4yrs

経営陣の近況

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06

Recent updates

Incyte: The Worst Has Been Avoided

Jun 16

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Sep 15

Incyte wins approval of Pemazyre for rare blood cancer

Aug 26

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

Aug 02

With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Jul 27

Incyte Corp. Should Move Higher (Technical Analysis)

Jul 18

Incyte: Growth Drivers Are Coming

Jun 17

Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures

Apr 14

Incyte: All Atention On Opzelura

Mar 21

Incyte: Still Has Room To Grow

Jan 24

Incyte: The Right Time To Buy The Stock

Dec 28

CEO報酬分析

Incyte の収益と比較して、Herve Hoppenot の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	US$745m
Dec 31 2023	US$17m	US$1m	US$598m
Sep 30 2023	n/a	n/a	US$425m
Jun 30 2023	n/a	n/a	US$366m
Mar 31 2023	n/a	n/a	US$324m
Dec 31 2022	US$17m	US$1m	US$341m
Sep 30 2022	n/a	n/a	US$876m
Jun 30 2022	n/a	n/a	US$945m
Mar 31 2022	n/a	n/a	US$933m
Dec 31 2021	US$14m	US$1m	US$949m
Sep 30 2021	n/a	n/a	US$535m
Jun 30 2021	n/a	n/a	US$338m
Mar 31 2021	n/a	n/a	US$478m
Dec 31 2020	US$16m	US$1m	-US$296m
Sep 30 2020	n/a	n/a	-US$335m
Jun 30 2020	n/a	n/a	-US$191m
Mar 31 2020	n/a	n/a	-US$376m
Dec 31 2019	US$15m	US$1m	US$447m
Sep 30 2019	n/a	n/a	US$405m
Jun 30 2019	n/a	n/a	US$306m
Mar 31 2019	n/a	n/a	US$253m
Dec 31 2018	US$9m	US$996k	US$109m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$102m
Mar 31 2018	n/a	n/a	-US$167m
Dec 31 2017	US$16m	US$967k	-US$313m

報酬と市場: Herveの総報酬 ($USD 16.66M ) は、 US市場 ($USD 13.53M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Herveの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Herve Hoppenot (64 yo)

10.4yrs

在職期間

US$16,659,526

報酬

Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Herve Hoppenot	CEO & Chairman	10.4yrs	US$16.66m	0.15% $ 21.3m
Pablo Cagnoni	President and Head of Research & Development	1.1yrs	US$16.57m	データなし
Christiana Stamoulis	Executive VP & CFO	5.3yrs	US$5.08m	0.010% $ 1.5m
Barry Flannelly	Executive VP & GM of North America	9yrs	US$4.09m	0.0049% $ 685.7k
Steven Stein	Executive VP & Chief Medical Officer	9.3yrs	US$5.63m	0.0011% $ 159.2k
Thomas Tray	VP of Finance	2.3yrs	データなし	0.0032% $ 439.9k
Michael Morrissey	Executive VP & Head of Global Technical Operations	8.4yrs	データなし	0.016% $ 2.3m
Ben Strain	Head of Investor Relations	no data	データなし	データなし
Sheila Denton	Executive VP	less than a year	データなし	データなし
Pamela Murphy	Vice President of Investor Relations & Corporate Communications	no data	データなし	データなし
Paula Swain	Executive Vice President of Human Resources	21.8yrs	US$1.31m	0.021% $ 2.9m
Vijay Iyengar	Executive VP of Global Medical Affairs	no data	US$3.30m	0.0054% $ 761.1k

8.4yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: INCYの経営陣は経験豊富で経験豊富です（平均在職期間は8.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Herve Hoppenot	CEO & Chairman	10.4yrs	US$16.66m	0.15% $ 21.3m
Jean-Jacques Bienaime	Independent Director	9.4yrs	US$478.76k	0.0069% $ 962.2k
Julian Baker	Independent Lead Director	22.6yrs	US$512.76k	0.32% $ 44.7m
Otis Brawley	Independent Director	2.8yrs	US$454.76k	0.0026% $ 367.3k
Jacqualyn Fouse	Independent Director	7.4yrs	US$466.26k	0.0062% $ 868.7k
Edmund Harrigan	Independent Director	4.5yrs	US$482.26k	0.0058% $ 814.2k
Katherine High	Independent Director	4.3yrs	US$454.76k	0.0036% $ 495.8k
Paul Clancy	Independent Director	9.4yrs	US$479.76k	0.0070% $ 980.4k
Susanne Schaffert	Independent Director	1.7yrs	US$444.76k	0.0013% $ 180.2k

7.4yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: INCYの取締役会は経験豊富であると考えられます ( 7.4年の平均在任期間)。

Incyte マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Executive VP & GM of North America recently sold US$1.1m worth of stock

Executive VP & GM of North America notifies of intention to sell stock

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Executive VP & Chief Medical Officer recently sold US$1.4m worth of stock

Recent updates

Incyte: The Worst Has Been Avoided

Executive VP & GM of North America recently sold US$1.1m worth of stock

Executive VP & GM of North America notifies of intention to sell stock

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte: A Potential GARP Superstar

Incyte Corporation Provides Earnings Guidance for 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Executive VP & Chief Medical Officer recently sold US$1.4m worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Earnings Guidance for the Year 2023

Consensus EPS estimates increase by 21%

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Price target decreased by 7.5% to US$82.42

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive VP & Chief Scientific Officer exercised options to buy US$287k worth of stock.

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Insider exercised options and sold US$115k worth of stock

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Executive VP & Chief Medical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement

Incyte wins approval of Pemazyre for rare blood cancer

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo

Incyte Corp. Should Move Higher (Technical Analysis)

Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022

Insider notifies of intention to sell stock

Incyte: Growth Drivers Are Coming

マネジメント基準チェック /44